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Figure 1. Overall survival (OS) and event-free survival (EFS).
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Background: Allogeneic hematopoietic cell transplantation
(HCT) is the only treatment option able to prevent progressive
neurodegenerative disease in a selected group of mucopoly-
saccharidoses (MPS)disorders.However, itsusewashistorically
limited by the high risk of graft failure and HCT-related
morbidityandmortality. Therefore in2005, theEuropeanBlood
and Marrow Transplantation group developed transplantation
guidelines forHCT inMPS patients.Weprospectively evaluated
the outcomes of HCT in MPS patients, complying with these
international guidelines in two centers performing the highest
numbers of HCT in MPS patients in Europe.
Methods: Two consecutive conditioning regimens were
used, either Busulfan/Cyclophosphamide (Bu/Cy) or Fludar-
abine/Busulfan (Flu/Bu)-based, both with exposure-targeted
intravenous Busulfan. A non-carrier matched sibling donor
(MSD) or an identical unrelated cord blood (UCB, 6/6 on in-
termediate resolution) or identical matched unrelated donor
(MUD, 10/10 on high-resolution typing) were considered
preferred donors. If not available, a mismatched UCB donor
was used.
Results: 62 MPS patients were included (56 MPS type I e
Hurler, 2 MPS type II, 2 MPS type III, and 2 MPS type VI); 29
receiving a BuCy, 33 a FluBu-based conditioning regimen.
Median age at HCTwas 13.5 (range 3-44) months. 41 patients
received an UCB donor, 17 a MSD, and 4 a MUD. High overall
survival (95.2%) and event-free survival (90.3%) were ach-
ieved (Figure 1). All three patients with graft failure received
a second HCT and are alive and with successful donor
engraftment at latest follow-up. A mismatched donor
predicted for lower event-free survival (p¼0.04). The
probability of aGVHD grade II-IV was 13.3%, while 14.8% of
the patients were diagnosed with cGVHD (1.9% extensive).
A higher age at HCT was a predictor for both aGVHD
(p¼0.001) and cGVHD (p¼0.01). The use of a mismatched
donor was a predictor for aGVHD (p¼0.01). Full-donor
chimerism and normal enzyme levels were found in 88.2%
and 95.1% of the patients, respectively. Higher rates of full-
donor chimerismwere achieved in UCB recipients (p¼0.002).
Conclusion: If complying with the international HCT
guidelines, HCT in MPS patients results in high safety and
efﬁcacy. This allows extension of HCT to more attenuated
MPS types such as MPS type I e Hurler-Scheie. As a younger
age at HCT is associated with reduction of HCT-related
toxicity, newborn screening may further increase safety.90
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Background: The combination of Clofarabine + Fludarabine
+ Busulfan (CloFluBu) was found to have synergistic anti-
leukemic activity against ALL and AML blasts in vitro
(Andersson et al: BBMT 2011). As TBI induces signiﬁcant late
effects in childhood ALL, and AML patients have high relapse
rates, we hypothesized that CloFluBu may be an interesting
alternative to TBI in ALL and add anti-leukemic activity in
AML. Within the “Dutch COG HCT Working Group” we pro-
spectively studied the outcomes of CloFluBu-conditioning
regimen for lymphoblastic and myeloid malignancies.
Methods: Patients from the 2 pediatric HCT programs (LUMC
and UMC Utrecht) with a lymphoblastic or myeloid malig-
nancy were included from Aug-2011 to present. Clofarabine
30mg/m2 was given in 1 hour, followed by Fludarabine
10mg/m2 in 1 hour followed by a 3-hour infusion of once
daily targeted busulfan (weight-based dosing: with thera-
peutic drug monitoring). Thymoglobulin was added in un-
related donors (except in AML patients receiving cord blood:
CB) and GvHD prophylaxis was according to standard pro-
tocols. The cumulative target area under the curve (AUC) for
Bu was 90 mg*h/L. Primary endpoint: leukemia free survival
(LFS) and overall survival (OS). Other endpoints: acute and
chronic graft-versus-host disease (GvHD), VOD, non-infec-
tious lung injury, neutrophil (@day60) and thrombocyte
engraftment (@day 180). A predictor analysis was performed
using Cox Proportional Hazard Models.
Results: 62 patients were included: 28 AML-CR2,14 ALL-CR1,
3 Infant-ALL, 11 ALL-CR2/3, 6 other (4 MDS, 2 CML, 1CNL).
10/19 ALL-CR1-3 patients with available MRD status prior to
HCT were positive: 4 >10e-3 and 6 < 10e-3. Donors used: 25
unrelated CB, 14 (matched) Family donors (FD; 1 Haplo-
identical) and 23 Matched Unrelated Donors. Median age at
HCT: 10.9 (0.5-17.9) years. Median follow-up 298 (range
18-1182) days. The estimated 2-year OS/LFS was 74+/-7%
